The biological rationale behind the intervention is well established. In intubated patients, the endotracheal tube cuff is inflated to create a seal against the tracheal wall, protecting the lower airways from contaminated secretions pooling above the cuff. Yet no cuff, regardless of its material or shape, guarantees a complete seal. Microscopic channels form within the inflated cuff wall, allowing bacteria-laden fluid to seep downward into the trachea in a process known as microaspiration. This mechanism is considered the principal route by which VAP develops. Two logical countermeasures follow: keeping cuff pressure stable within a safe and effective range, and actively removing the subglottic secretions before they can migrate past the cuff. Both sound simple, but in practice they are surprisingly difficult to achieve reliably.

Manual cuff pressure checks, typically performed intermittently by nursing staff, are inherently limited. Cuff pressure fluctuates with body repositioning, changes in ventilator settings, and shifts in the depth of sedation, meaning that a pressure measured and corrected every eight hours may drift far out of range within minutes. Meta-analytic evidence has suggested that automated continuous cuff pressure control systems can reduce VAP risk, and a parallel body of evidence supports subglottic secretion drainage, which can be delivered either intermittently or continuously. What remained poorly understood was whether the continuous suctioning approach—and an automated, integrated system combining both measures—could translate into meaningful clinical benefits.

Into this gap stepped De Pascale and colleagues, who designed the MICROINHALO trial, a multicenter cluster-randomized study published in Intensive Care Medicine. The trial compared an automated strategy—continuous cuff pressure control paired with continuous subglottic secretion drainage—against a conventional approach of manual cuff pressure measurements at minimum every eight hours combined with intermittent, hourly suctioning. A distinctive feature of the automated system was its personalization: rather than relying on direct pressure measurements alone, cuff inflation was steered by monitoring carbon dioxide above the cuff, effectively detecting leakage around the cuff and adjusting inflation accordingly.

On the mechanistic level, the intervention performed as intended. Patients in the automated group had fewer cuff pressure observations outside the target range, and within the manual control group, most measurements fell substantially below the lower target boundary—a finding that underscores just how unreliable manual checks can be. The automated group also accumulated a greater total volume of drained secretions, indicating that continuous drainage was indeed removing more potentially infectious material from the subglottic space. Yet when the researchers examined their primary outcome—bacterial tracheobronchial colonization on day three—they found no difference between the groups. The headline secondary finding, however, was striking: patients receiving the automated strategy experienced significantly less microbiologically documented VAP, at 10.2 percent compared with 19.5 percent in the conventional care group.

An editorial accompanying the trial, authored by Stijn Blot, Elena Conoscenti, and Alexandre Boyer, has framed the findings through several competing lenses, and their analysis is where the story becomes genuinely fascinating. From what the editorialists call the scientist’s perspective, the trial leaves important questions unresolved. Combining two interventions in a single device makes it impossible to disentangle the individual contribution of each component. Moreover, because the automated system required a dedicated central monitor for every intubated patient, questions of cost and environmental footprint arise—considerations that, the editorialists argue, demand convincing evidence of superiority before widespread adoption.

That evidence, they contend, is not yet convincing, for several technical reasons. First, while the device drained more secretions, whether that volume stands above or below an ideal threshold—which remains unknown—cannot be determined. Second, because cuff pressure was steered by carbon dioxide leakage rather than direct measurement, pressures exceeded the 30 cm H2O safety threshold in roughly 10 percent of measurements. Excessive cuff pressure risks tracheal edema and dysphagia, and a previous pilot study of the device had reported tracheal mucosal damage in 16.7 percent of patients versus 10 percent with a conventional system, a nonsignificant difference in an underpowered comparison.

The choice of primary outcome also draws scrutiny. Day-3 tracheobronchial colonization, the editorialists argue, is an imperfect surrogate for microaspiration. Roughly half of the enrolled patients were initially intubated for suspected pneumonia, and clinically important baseline differences in isolated microorganisms existed between groups, potentially skewing subsequent colonization dynamics. Colonization is further confounded by antibiotic exposure, and with 76 percent of patients receiving antibiotics in the early days of the study, antibiotic pressure was substantial. Supporting the skeptical reading, tracheal aspirate biomarkers of microaspiration—amylase and pepsin, measured at one center—showed no reduction in the intervention arm, with pepsin levels actually higher. And although VAP rates fell, only 38 percent of VAP episodes were diagnosed by bronchoalveolar lavage, the most specific diagnostic method, meaning the apparent reduction rests partly on a less rigorous diagnostic approach. No differences emerged in antibiotic use, ventilator-free days, ICU-free days, or mortality.

Yet the clinician’s perspective, as the editorial lays out, offers a more forgiving interpretation. The apparent contradiction—no difference in colonization but fewer documented pneumonias—can be reconciled if microaspiration occurred at similar rates in both groups but to a greater extent in controls. Under this reasoning, the intervention reduces but does not eliminate microaspiration, and the larger bacterial inocula in the manual group crossed the threshold for frank pneumonia more often. Furthermore, pneumonia diagnosed without bronchoalveolar lavage is not the same as no pneumonia; a substantial proportion of these microbiologically documented episodes likely represent true infection. Colonization does not suddenly transform into pneumonia—it evolves through an interplay between host defenses and bacterial inoculum and virulence, and clinically relevant infection may develop before the conventional diagnostic threshold of 10⁴ colony-forming units per milliliter is reached.

The guideline perspective adds a final, sobering layer. Many international guidelines only “suggest,” rather than “recommend,” preventive measures that lack demonstrated reductions in ventilation days or mortality. Proving such outcomes is statistically daunting: assuming a baseline ventilation duration of 10 days and an excess of 7 ventilated days when VAP develops, halving VAP incidence from 20 to 10 percent would shorten mean ventilation by only 0.7 days—requiring roughly 6,400 patients to demonstrate significance, far beyond what any existing meta-analysis has accumulated. The same arithmetic applies to mortality. If VAP itself matters as an outcome, the editorialists ask, why insist on additional downstream benefits before implementation—especially when multiple preventive measures and care bundles have already been shown to be cost-effective? The real question, they suggest, is which combination of preventive measures to prefer, and accepting microbiologically documented VAP as a valid endpoint may be reasonable provided the diagnostic standard is acceptable.

So, do we need more proof or more perspective? The MICROINHALO trial demonstrates that sophisticated technology can tighten cuff pressure control and clear more secretions, and that these mechanistic gains were accompanied by a near-halving of microbiologically documented pneumonia. Whether that suffices to change practice depends on how the critical care community weighs surrogate outcomes against hard endpoints, diagnostic specificity against clinical plausibility, and the costs of innovation against the costs of preventable infection. Until the field agrees on how much evidence is enough, the editorialists conclude, the place of automated cuff pressure control and subglottic secretion drainage in VAP prevention will remain a matter of perspective rather than proof—a debate that will shape both patient care and the design of the next generation of endotracheal tubes.

The study, led by L.W. Hoornenborg, L.W. Hafner and C.J. Wright and published in Pediatric Research, focuses on infants born extremely preterm. These babies are commonly exposed to invasive ventilation, oxygen therapy and inflammatory stress before their lungs have completed critical stages of development. Bronchopulmonary dysplasia, or BPD, can emerge when immature lung tissue is injured by the combined effects of prematurity, oxygen, mechanical ventilation and infection.

Paracetamol, also known as acetaminophen, is frequently administered to newborns to relieve pain associated with procedures such as venous access, intubation, surgery or the placement of chest drains. It is also used in some neonatal settings to treat discomfort or fever. Compared with opioids and certain sedative drugs, paracetamol is often viewed as a relatively gentle option, although its effects in extremely immature infants remain an active area of research.

The investigators used data from the BeNeDuctus trial, a randomized clinical study involving extremely preterm infants. The original trial examined strategies for managing a patent ductus arteriosus, a blood vessel that normally closes after birth but may remain open in premature babies. The secondary analysis used the trial’s detailed clinical records to investigate paracetamol exposure and subsequent respiratory outcomes, including the development of BPD.

This type of analysis can provide valuable information while also requiring careful interpretation. Because the infants were not randomly assigned to receive paracetamol, the drug may have been given to babies who were already more severely ill or who underwent more procedures. In epidemiology, this problem is known as confounding by indication: the reason a treatment is prescribed can itself be related to the outcome researchers are studying. A higher rate of BPD among infants receiving paracetamol, for example, would not automatically mean that paracetamol caused lung injury.

The biological question is complex. Paracetamol is metabolized differently in newborns than in older children and adults, partly because the liver and other organs are still developing. At therapeutic doses, it is generally considered an analgesic and antipyretic rather than a strong anti-inflammatory drug. However, experimental research has raised questions about oxidative stress, mitochondrial function and the possible effects of drug exposure during sensitive periods of lung development. These mechanisms remain theoretical in many clinical contexts and cannot be confirmed by an observational association alone.

BPD itself is not a single, uniform disease. Diagnostic definitions may include the infant’s need for supplemental oxygen or respiratory support at a specified postmenstrual age, and severity can range from relatively limited oxygen dependence to prolonged need for invasive ventilation. The condition reflects both the immature structure of the preterm lung and the effects of postnatal treatment. This makes it particularly important for studies to account for gestational age, birth weight, respiratory support, infection, patent ductus arteriosus and other factors that influence lung outcomes.

By drawing on a well-characterized trial population, the BeNeDuctus analysis offers a more structured setting than a routine retrospective hospital database. The researchers could examine the timing and extent of paracetamol exposure alongside neonatal characteristics and clinical outcomes. Nevertheless, the analysis remains secondary and observational with respect to analgesic use. Its findings can identify patterns and help refine future research, but they cannot establish that paracetamol independently causes, prevents or modifies BPD.

The study arrives at a time when neonatal teams are seeking safer approaches to pain management. Extremely preterm infants can experience repeated painful interventions, yet undertreated pain may also affect stress responses, sleep, neurodevelopment and later behavior. Clinicians therefore face a difficult balance: reducing procedural pain while avoiding unnecessary medication and limiting exposure to drugs whose long-term effects in the most immature infants are not fully understood. The new analysis adds to that discussion by examining respiratory health, one of the most consequential outcomes of extreme prematurity.

For families and clinicians, the central message is that the presence of paracetamol in an infant’s treatment history should be interpreted within the broader clinical picture. The BeNeDuctus findings may help guide the design of prospective studies that record pain severity, dosing, cumulative exposure and respiratory status in greater detail. Until stronger evidence is available, decisions about analgesia will continue to depend on individualized assessment, careful dosing and the principle that effective pain relief must be weighed against the distinctive vulnerabilities of the developing preterm infant.

Subject of Research: The association between paracetamol use as an analgesic and bronchopulmonary dysplasia risk in extremely preterm infants.

Article Title: Paracetamol as analgesic and risk of bronchopulmonary dysplasia in extremely preterm infants: a secondary analysis of the BeNeDuctus trial.

Article References: Hoornenborg, L.W., Hafner, L.W., Wright, C.J. et al. Paracetamol as analgesic and risk of bronchopulmonary dysplasia in extremely preterm infants: a secondary analysis of the BeNeDuctus trial. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05352-2

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05352-2

Keywords: paracetamol, acetaminophen, analgesia, extremely preterm infants, bronchopulmonary dysplasia, neonatal care, BeNeDuctus trial, premature lung development, respiratory outcomes

Preterm infants, especially those born before 32 weeks of gestation, frequently require respiratory assistance due to surfactant deficiency and structural immaturity of the lungs. Traditional approaches relying heavily on mechanical ventilation have been associated with complications such as bronchopulmonary dysplasia (BPD) and ventilator-induced lung injury. Consequently, clinicians and researchers have shifted focus towards non-invasive respiratory interventions, such as continuous positive airway pressure (CPAP) and less invasive surfactant administration techniques, aiming to minimize lung trauma while sustaining functional residual capacity.

The recent study by Payton, Biniwale, and Ramanathan, published in Pediatric Research, underscores the complexity of determining the optimal respiratory support protocol at birth. Their analysis integrates evolving clinical evidence and physiological insights to outline a nuanced intervention framework tailored for preterm infants. The key lies in achieving precise pressure delivery and timing to maintain alveolar stability and promote lung fluid clearance without triggering volutrauma or barotrauma—formidable challenges given the fragility of preterm pulmonary tissue.

A fundamental consideration is the initial stabilization phase immediately after birth when spontaneous breaths are often shallow or irregular. Positive pressure ventilation (PPV), though sometimes necessary, must be judiciously applied with the lowest effective pressures. Excessive pressure settings risk alveolar overdistension, which can exacerbate inflammation and disrupt the structural development of the pulmonary architecture. The research advocates for devices capable of delivering gentle but consistent support, dynamically adjusting to an infant’s respiratory effort, thereby achieving a delicate balance between aiding ventilation and preserving lung integrity.

This balance is complicated further by the heterogeneity among preterm infants, whose gestational ages, lung maturity, and comorbidities vary widely. A one-size-fits-all approach to respiratory support is emerging as inadequate. Instead, caregiver teams must incorporate real-time monitoring tools such as tidal volume measurements, oxygen saturation indices, and blood gas analyses to tailor respiratory interventions precisely. The study calls for broader implementation of individualized respiratory support algorithms, augmented by technological advances in monitoring and ventilatory control.

Further complicating the strategy mix is the burgeoning role of less invasive surfactant administration (LISA). Delivering surfactant without full intubation reduces airway trauma and mechanical ventilation exposure. The investigation highlights how LISA, coupled with CPAP, can constitute a highly effective initial respiratory strategy for many preterm infants, mitigating the inflammatory cascade associated with mechanical ventilation. However, successful implementation demands meticulous patient selection and technical proficiency.

The authors stress that targeting an intermediate level of respiratory support—not so aggressive as to cause lung damage, yet sufficient to avoid hypoxia and hypercapnia—is pivotal. This “happy medium” may be conceptualized as a dynamic equilibrium, continuously fine-tuned based on the infant’s evolving respiratory status. Such sophistication in clinical care necessitates interdisciplinary collaboration, comprehensive training, and robust protocols supported by emerging data from physiologic studies and randomized controlled trials.

Innovative respiratory management devices designed for neonates—offering features such as synchronized ventilation, automated pressure modulation, and enhanced humidification—represent promising tools to realize this middle ground. These technologies aim to harmonize respiratory assistance with the infant’s spontaneous breathing efforts, optimizing comfort and minimizing iatrogenic injury. The research encourages sustained investment in device innovation and rigorous clinical validation.

Additionally, the optimization of initial respiratory support has cascading downstream benefits. By preserving lung structure and function, the risk of chronic respiratory conditions, prolonged hospital stays, and long-term neurodevelopmental impairments may be mitigated. This approach not only improves immediate survival outcomes but also fosters enhanced quality of life trajectories for survivors of preterm birth—a central objective in neonatal medicine.

The article also points to the urgent need for further translational research to elucidate mechanistic pathways of ventilator-induced lung injury at the cellular and molecular levels in the preterm population. Understanding how mechanical forces interact with immature lung epithelium and immune cells will inform refinements in ventilatory protocols and pharmacologic adjuncts. Such insights promise to break new grounds in protective respiratory care paradigms.

Moreover, emerging biomarkers that detect early lung injury or inflammation could become invaluable tools in clinical decision-making. Integrating these biomarkers with ventilator settings and clinical parameters could personalize respiratory support even more finely, instigating preventive interventions before overt lung damage manifests. The study advocates for multidisciplinary collaborations involving neonatologists, pulmonologists, bioengineers, and basic scientists to accelerate progress in this domain.

In parallel with clinical and technological advances, educational initiatives remain crucial. The consistency and quality of respiratory support depend heavily on clinician expertise and adherence to evidence-based protocols. Simulation training in neonatal respiratory care, decision-support algorithms, and real-time feedback mechanisms can enhance caregiver competence and patient safety, ultimately contributing to better outcomes.

The study by Payton and colleagues thus encapsulates a holistic approach toward respiratory care immediately after birth for preterm infants. It champions a paradigm that transcends simplistic high versus low-pressure dichotomies in favor of context-sensitive, physiologically attuned respiratory strategies. As neonatal survival rates improve globally, the focus naturally pivots to optimizing the quality and durability of survival, with respiratory support at birth as a cornerstone.

In summary, the emerging “happy medium” in preterm infant respiratory support metaphorically and practically represents a Goldilocks zone: not too invasive, not too minimal, but just right in balancing the competing demands of oxygenation, ventilation, and lung protection. Achieving this balance requires synergistic clinical acumen, innovative technology, personalized monitoring, and ongoing research investment. The implications of this quest resonate profoundly in the neonatal intensive care units worldwide, underscoring a transformative moment in the care of the most vulnerable lives.

Subject of Research: Optimizing respiratory support strategies for preterm infants at birth to minimize lung injury and improve outcomes.

Article Title: In search of a happy medium for preterm infant respiratory support at birth.

Article References:
Payton, K., Biniwale, M. & Ramanathan, R. In search of a happy medium for preterm infant respiratory support at birth:. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04513-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04513-z

Mechanical ventilation, facilitated through endotracheal intubation, is often an indispensable intervention for patients undergoing surgeries or facing emergent respiratory failures. While lifesaving, intubation carries its own significant risks, including the development of ventilator-associated pneumonia, barotrauma-induced lung injury, and complications arising from extended sedation protocols necessary to ensure patient comfort during ventilation. Therefore, the transition from mechanical support to autonomous breathing is a critical juncture in patient care that demands precise and timely action.

Spontaneous breathing trials function as an essential component in assessing a patient’s readiness to breathe independently. During an SBT, patients undergo a reduction or cessation of ventilatory support, typically for durations ranging between 30 minutes to three hours, while clinicians closely monitor vital parameters such as heart rate, respiratory rate, oxygen saturation, and overall respiratory effort. Successful completion of this trial generally signals that the patient may be physiologically prepared to handle the workload of spontaneous respiration without mechanical assistance.

The investigative team, spanning a period from 2015 to 2023 and analyzing an extensive dataset of more than 3,000 patients, pursued two primary research questions: How frequently are patients extubated within six hours after passing an SBT? And what are the contributory factors influencing decisions to delay extubation despite favorable physiological indicators? Their retrospective cohort study offers invaluable insight into these clinical ambiguities.

Results showed that only 62.3% of patients who passed the spontaneous breathing trial were extubated within six hours. Conversely, a significant subset, nearly 37.7%, remained intubated past this window, subsequently enduring an average of two additional days connected to the ventilator. This prolongation highlights a striking discrepancy between physiological readiness and clinical practice behavior, suggesting a potential gap in extubation protocols or risk tolerance.

Multiple factors influencing delayed extubation were identified, many correlating with known clinical barriers. Decreased levels of consciousness frequently impede timely removal of the breathing tube since adequate neurological status is imperative for airway protection. Similarly, the administration of either low or high doses of vasopressors, medication that modulates blood pressure in critically ill patients, indicates hemodynamic instability—a contraindication for immediate extubation. Additionally, impending invasive procedures within 24 hours post-trial created further hesitation among clinicians to withdraw ventilatory support prematurely.

However, intriguingly, over half of the patients who remained intubated lacked these standard risk factors typically justifying delayed extubation. In this notable group, the major determinant cited was “attending preference,” an expression reflecting individualized clinical judgment or perhaps institutional cultural nuances that could affect decision-making. This subjective element points toward a complexity beyond purely physiological considerations, encompassing elements of risk aversion, communication dynamics, or varying interpretations of extubation readiness guidelines.

The implications of these findings underscore the indispensable role of coordinated interdisciplinary communication involving respiratory therapists, nursing staff, and physicians. Such collaboration ensures that all dimensions of patient status, including neurological alertness, hemodynamic stability, and procedural scheduling, are comprehensively evaluated. The presence and involvement of family members and caregivers also emerged as a significant positive influence, promoting patient alertness and potentially facilitating more timely extubation decisions.

This study encourages critical introspection within critical care environments, urging the development of standardized extubation protocols that minimize subjective delays without compromising patient safety. Emphasizing evidence-based criteria alongside clinical judgement can harmonize practices, reduce compounding ventilator-related risks, and improve patient outcomes through more efficient liberation from mechanical ventilation.

The research, led by Dr. Anna Barker and Dr. Michael Sjoding from the University of Michigan’s Division of Pulmonary and Critical Care Medicine, harnessed the power of electronic health records, illuminating practice patterns inaccessible through traditional observational studies. Their pioneering work sets a foundational precedence for future investigations that seek to unravel the nuances of clinical decision-making and implement engineering solutions or algorithmic tools to assist bedside clinicians.

Published in the esteemed Annals of the American Thoracic Society, this retrospective cohort study affirms the broad impact of human factors in medical interventions and accentuates the paramount importance of timely extubation. As mechanical ventilation remains a mainstay of critical care, optimizing the transition from ventilator dependence to autonomous respiration promises both to mitigate iatrogenic complications and to economize healthcare resources.

This compelling work paves the way for continued research into the psychosocial and institutional determinants of extubation timing, advocating for prospective trials and qualitative studies that interrogate the motivations behind “attending preference” and the potential for targeted educational interventions. The ultimate objective is to establish consensus-driven, patient-centered extubation strategies that balance safety with efficiency, reducing unnecessary ventilator exposure while respecting individual clinical circumstances.

As ventilator-associated complications contribute significantly to morbidity and mortality in intensive care settings, the elucidation of factors behind extubation delays represents a critical step forward. The study’s revelations invite the critical care community to embrace an integrated approach—a fusion of rigorous clinical guidelines, effective multidisciplinary communication, and attentive patient engagement—to improve the quality and timing of extubation worldwide.

Subject of Research: Extubation practices following successful spontaneous breathing trials and factors influencing ventilator removal timing in hospitalized patients.

Article Title: Providers Consistently Delay Extubation After Successful Spontaneous Breathing Trials: A Retrospective Cohort Study

Web References: DOI: 10.1513/AnnalsATS.202502-188OC

References: Annals of the American Thoracic Society

Keywords: Health care, Clinical medicine